← Leaderboards
Yu Chen
Sloan-Kettering Inst Can Research
$11,691,795
Attributed
$14,944,193
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$23,555,033 · 10
By mechanism
P50$10,306,798 · 5
R01$5,432,097 · 2
U01$5,129,971 · 1
U54$1,890,422 · 1
K08$795,745 · 1
Top collaborators
- Phillip Andrew Futreal5 shared
- Nora M Navone4 shared
- Howard I Scher3 shared
- Michael J Morris1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Charles L Sawyers$34,701,646
- David B. Solit$21,393,031
- Hikmat Al-Ahmadie$4,559,862
- Elisa De Stanchina$4,011,743
- Alexander Drilon$4,847,187
Others in their field
Top investigators on “Molecular”
- David Heimbrook · Leidos Biomedical Research, Inc.$871,088,761
- Leonard Freedman · Leidos Biomedical Research, Inc.$468,573,385
- Richard Webby · St. Jude Children'S Research Hospital$254,843,170
- Larry Arthur$238,531,074
- Gregory H Reaman · National Childhood Cancer Foundation$230,630,913
- Ralph Parchment · Leidos Biomedical Research, Inc.$193,231,914
Research focus
MolecularMalignant Neoplasm Of ProstateTissuesMutationPathway InteractionsGenesOrganoidsProstateProstate Cancer ModelResistanceTumorTherapy ResistantResponseAndrogen ReceptorMalignant NeoplasmsSignal TransductionGeneticMediatingIn VitroGrowthGene ExpressionResearch PersonnelGenetically Engineered MouseCell Line
Grant awards (37)
SPORE in Prostate Cancer$2,126,579
P50 · FY2025 · CA · contact PI
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma$1,204,605
R01 · FY2025 · CA · contact PI
Core D: Preclinical Models Core$212,658
P50 · FY2025 · CA · contact PI
SPORE in Prostate Cancer$1,773,356
P50 · FY2024 · CA
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma$572,189
R01 · FY2024 · CA · contact PI
Core D: Preclinical Models Core$161,198
P50 · FY2024 · CA · contact PI
SPORE in Prostate Cancer$2,345,974
P50 · FY2023 · CA
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,005,497
U01 · FY2023 · CA
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma$590,257
R01 · FY2023 · CA · contact PI
Core D: Preclinical Models Core$212,401
P50 · FY2023 · CA · contact PI
SPORE in Prostate Cancer$2,364,931
P50 · FY2022 · CA
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,005,497
U01 · FY2022 · CA
Defining the role of histone H3K4 mono-methyltransferase dysfunction in urothelial carcinoma$602,303
R01 · FY2022 · CA · contact PI
Core D: Preclinical Models Core$213,993
P50 · FY2022 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,026,019
U01 · FY2021 · CA
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance$499,575
R01 · FY2021 · CA · contact PI
Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy$475,484
U54 · FY2021 · CA · contact PI
Core E: Organoids Core$66,672
P50 · FY2021 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,051,939
U01 · FY2020 · CA
Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy$510,416
U54 · FY2020 · CA · contact PI
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance$499,575
R01 · FY2020 · CA · contact PI
Core E: Organoids Core$161,778
P50 · FY2020 · CA · contact PI
Patient-Derived Models of Prostate Cancer for Personalized Medicine$1,041,019
U01 · FY2019 · CA
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance$481,696
R01 · FY2019 · CA · contact PI
Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy$471,200
U54 · FY2019 · CA · contact PI
Core E: Organoids Core$162,633
P50 · FY2019 · CA · contact PI
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance$483,284
R01 · FY2018 · CA · contact PI
Core E: Organoids Core$170,923
P50 · FY2018 · CA · contact PI
Understanding the role of an aberrant hepatic nuclear transcription circuit in prostate cancer tumorigenesis and castration resistance$498,613
R01 · FY2017 · CA · contact PI
Project 2: Reversing resistance caused by lineage plasticity through epigenetic therapy$433,322
U54 · FY2017 · CA · contact PI
Core E: Organoids Core$171,580
P50 · FY2017 · CA · contact PI
Core E: Organoids Core$162,122
P50 · FY2016 · CA · contact PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.$159,149
K08 · FY2013 · CA · contact PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.$159,149
K08 · FY2012 · CA · contact PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.$159,149
K08 · FY2011 · CA · contact PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.$159,149
K08 · FY2010 · CA · contact PI
Understanding the roles of TMPRSS2 and ERG in pathogenesis of prostate cancer.$159,149
K08 · FY2009 · CA · contact PI